Guangzhou Innogen Pharmaceutical Group (HKG:2591) raised HK$634.7 million in net proceeds from its initial public offering in Hong Kong, according to a Thursday after-market Hong Kong bourse filing.
The pharmaceutical firm priced its 36,556,400 H-shares at HK$18.68 apiece.
The Hong Kong public offer was 5,341.66 times oversubscribed, with the final allocation of 3,655,800 shares, or about 10% of the total offering, unchanged from the initial allotment.
The international offering was 10.67 times subscribed, with the final number of shares offered remaining at 32,900,600.
Cornerstone investors June Star Global, Ginkgo Capital Global Fund - SPC XtalPi AI Fund SP, Marketingforce Management, Deng Haifeng, and Li Huifeng were allotted a combined 4,201,000 shares, or about 11.49% of the global offering.
Guangzhou Innogen Pharma is set to debut on the Hong Kong bourse on Friday, Aug. 15.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。